|
Hello,
The Advisory Committee on Immunization Practices (ACIP) met on May 5 to receive updates and discuss the vaccines for rabies and dengue. The workgroup did not vote on any recommendations in the meeting.
The rabies pre-exposure prophylaxis presentation and dialogue was a continuation of the discussion at the February ACIP meeting. The workgroup received additional information about rabies pre-exposure prophylaxis in children. The rabies post-exposure prophylaxis topic was focused on better clarifying and communicating the complicated existing recommendations.
The workgroup had an in-depth discussion about the dengue vaccine, Dengvaxia. Dengvaxia should only be given to patients that have previously been infected with dengue since it may increase the risk of severe dengue in patients who are vaccinated but have not previously been infected. The ACIP workgroup used the Evidence to Recommendations Framework to explore whether 3 doses of Dengvaxia should be administered routinely to persons 9–16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas (e.g., Puerto Rico). Dengvaxia requires a more complex implementation process than other vaccines since patients must receive a lab test showing a past infection with dengue before receiving the vaccine. Much of the conversation revolved around implementation concerns related to the vaccine. There was interest expressed in storing lab test results in IIS.
The next scheduled ACIP meeting is Wednesday, May 12, and will address expanding the age recommendations for the Pfizer COVID-19 vaccine to include children 12–15 years of age.
Thank you.
|
